TY  - JOUR
U1  - Zeitschriftenartikel, wissenschaftlich - begutachtet (reviewed)
A1  - Pfützner, Andreas
A1  - Standl, Eberhard
A1  - Strotmann, Hermann-Josef
A1  - Schulze, Jan
A1  - Hohberg, Cloth
A1  - Lübben, Georg
A1  - Pahler, Sabine
A1  - Schöndorf, Thomas
A1  - Forst, Thomas
T1  - Association of high-sensitive C-reactive protein with advanced stage β-cell dysfunction and insulin resistance in patients with type 2 diabetes mellitus
JF  - Clinical Chemistry and Laboratory Medicine
N2  - Background: Type 2 diabetes mellitus is associated with increased cardiovascular risk. One laboratory marker for cardiovascular risk assessment is high-sensitivity C-reactive protein (hsCRP).
Methods: This cross-sectional study attempted to analyze the association of hsCRP levels with insulin resistance, β-cell dysfunction and macrovascular disease in 4270 non-insulin-treated patients with type 2 diabetes [2146 male, 2124 female; mean age ±SD, 63.9±11.1years; body mass index (BMI) 30.1±5.5kg/m2; disease duration 5.4±5.6years; hemoglobin A1c (HbA1c) 6.8±1.3%]. It consisted of a single morning visit with collection of a fasting blood sample. Observational parameters included several clinical scores and laboratory biomarkers.
Results: Stratification into cardiovascular risk groups according to hsCRP levels revealed that 934 patients had low risk (hsCRP <1mg/L), 1369 patients had intermediate risk (hsCRP 1–3mg/L), 1352 patients had high risk (hsCRP >3–10mg/L), and 610 patients had unspecific hsCRP elevation (>10mg/L). Increased hsCRP levels were associated with other indicators of diabetes-related cardiovascular risk (homeostatic model assessment, intact proinsulin, insulin, BMI, β-cell dysfunction, all p<0.001), but showed no correlation with disease duration or glucose control. The majority of the patients were treated with diet (34.1%; hsCRP levels 2.85±2.39mg/L) or metformin monotherapy (21.1%; 2.95±2.50mg/L hsCRP). The highest hsCRP levels were observed in patients treated with sulfonylurea (17.0%; 3.00±2.43mg/L).
Conclusions: Our results indicate that hsCRP may be used as a cardiovascular risk marker in patients with type 2 diabetes mellitus and should be evaluated in further prospective studies.
KW  - homeostatic model assessment (HOMA)
KW  - intact proinsulin
KW  - type 2 diabetes
KW  - high-sensitivity C-reactive protein (hsCRP)
KW  - insulin resistance
UN  - https://nbn-resolving.org/urn:nbn:de:hbz:1044-opus-28723
SN  - 1437-4331
SS  - 1437-4331
U6  - https://doi.org/10.1515/CCLM.2006.108
DO  - https://doi.org/10.1515/CCLM.2006.108
PM  - 16681424
VL  - 44
IS  - 5
SP  - 556
EP  - 560
PB  - de Gruyter
CY  - Berlin
ER  -